Investment Rating - The report maintains a "BUY" rating for FIT Hon Teng, with a target price of HK$7.42, representing a potential upside of 35.8% from the current price of HK$5.46 [3][13]. Core Insights - FIT Hon Teng's FY25 revenue increased by 12% year-over-year to US$5.0 billion, which is largely in line with expectations, while net profit grew by 2% year-over-year to US$156 million, falling short of both the report's and consensus estimates by 8% and 12% respectively, primarily due to a higher effective tax rate [1][8]. - Management expressed optimism regarding the cloud and datacenter segments, forecasting a 70% year-over-year revenue growth for these areas in FY26, and has raised the guidance for the cloud revenue mix for FY26-28 to mid-20%/high-20%/low-30% [1][7]. - The report highlights upcoming catalysts such as GTC/OFC events and AI server product launches, which are expected to drive further growth [1][13]. Financial Performance Summary - FY25 revenue was reported at US$5,003 million, reflecting a 12.4% year-over-year growth, while net profit was US$156.7 million, a modest increase of 1.5% year-over-year [2][8]. - The gross profit margin for FY25 was 18.9%, slightly down from 19.7% in FY24, while the operating profit margin decreased to 5.7% from 7.3% in FY24 [8][10]. - For FY26, revenue is projected to reach US$5.754 billion, with a year-over-year growth of 15%, and net profit is expected to increase significantly to US$315.2 million, representing a 101.2% growth [2][10]. Segment Performance - The cloud/datacenter segment showed strong momentum with a 38% year-over-year growth, driven by AI connectivity solutions and new AI server deliveries [7][9]. - The automotive segment experienced a remarkable 94% year-over-year growth, attributed to the consolidation of the Auto-Kabel business [7][9]. - The smartphone segment faced a decline of 13% year-over-year, while consumer interconnects grew by 7% year-over-year, indicating mixed performance across different product lines [7][9]. Valuation Metrics - The report indicates an attractive valuation with a P/E ratio of 15.7x for FY26 and 11.5x for FY27, suggesting potential for re-rating as AI revenue contributions increase [1][13]. - The target price of HK$7.42 is based on a P/E of 21x for FY26, reflecting a higher valuation multiple due to the anticipated increase in AI revenue mix [3][13].

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [2][32]. Core Insights - The report highlights that the MSCI China Healthcare Index has increased by 5.0% since early 2026, outperforming the MSCI China Index by 6.2%. However, there has been a recent pullback in the pharmaceutical sector, with the MSCI China Healthcare Index declining by 9% since January 15, 2026, and the Hang Seng Biotech Index dropping by 13% during the same period. This adjustment is attributed to a lack of short-term catalysts and sector rotation leading to capital outflows from the pharmaceutical sector [1]. - The report emphasizes the rapid development of AI technology in drug discovery, which is expected to transform the paradigm of innovative drug development. Major global pharmaceutical companies are increasingly privatizing and upgrading their core AI infrastructure to create significant data barriers. For instance, Eli Lilly launched its AI factory, LillyPod, equipped with advanced computing capabilities [5]. - The report notes that Chinese AI pharmaceutical companies are thriving, with business models focusing on AI SaaS/CRO services and self-developed pipelines. Significant overseas collaborations have been established, validating the strength of these AI platforms [5]. Summary by Sections Industry Overview - The report discusses the recent pullback in the pharmaceutical sector and the implications for investment opportunities, particularly in innovative drug development and AI applications [1][5]. Company Ratings - The report recommends buying shares in the following companies: - 三生制药 (Sangfor) - 7,117.7 million USD market cap, target price 37.43, 71% upside [2] - 加科思 (JiaKuoSi) - 625.4 million USD market cap, target price 10.34, 67% upside [2] - 固生堂 (GuShengTang) - 857.3 million USD market cap, target price 44.95, 63% upside [2] - 药明合联 (WuXi AppTec) - 9,673.9 million USD market cap, target price 88.00, 39% upside [2] - 中国生物制药 (China National Pharmaceutical Group) - 14,508.2 million USD market cap, target price 9.40, 55% upside [2] Market Trends - The report indicates that the trend of Chinese innovative drugs going global continues, with multinational corporations showing increased enthusiasm for acquiring Chinese assets. The report also highlights the ongoing demand for innovative research and development within China [5].

Investment Rating - The industry is rated as "Outperform" indicating that the sector is expected to perform better than the market benchmark over the next 12 months [16]. Core Insights - The report emphasizes the importance of client incremental value creation in the software and IT services sector, particularly in response to competitive pressures from AI models [2][4]. - Leading companies in application software have established competitive barriers based on deep understanding and utilization of customer data, mature workflow products, and reliable AI systems [2][9]. - The transition to a hybrid pricing model is seen as a key driver for long-term revenue growth, with companies like Salesforce and ServiceNow successfully implementing such models [2][11]. - The report highlights the ongoing internal application of AI to enhance operational efficiency, which is expected to support profit margins across various companies [2][4]. Summary by Relevant Sections Application Software - Leading companies are focusing on enhancing client value through reliable workflows and understanding of data, which helps mitigate AI-related competition [2][4]. - Salesforce has established four competitive barriers, including deep data understanding and a robust AI system, while ServiceNow emphasizes cross-departmental integration capabilities [2][9]. Hybrid Pricing Model - Salesforce has developed a hybrid pricing model that includes per-user and usage-based fees, receiving positive feedback from clients [2][10]. - ServiceNow is also transitioning to a hybrid model, which balances budget predictability for clients with revenue opportunities for the company [11][12]. AI Integration and Efficiency - Companies are leveraging AI to improve internal operations, with Salesforce reporting significant efficiency gains in customer service and sales [2][4]. - ServiceNow has noted that AI allows for a high percentage of IT requests to be resolved independently, leading to substantial cost savings [2][4]. Company Recommendations - The report recommends focusing on companies capable of transitioning to hybrid pricing models and benefiting from AI-driven revenue growth, specifically highlighting Palo Alto Networks and Datadog as key investment opportunities [2][4][8].

Industry Insights - The U.S. software and IT services sector is focusing on client value creation, with leading companies emphasizing their competitive advantages in enterprise data, product deployment, and workflow governance [5] - There is a notable shift towards hybrid pricing models in application software, driven by the need to demonstrate value based on results [5] - Network security and infrastructure software are facing lower concerns regarding AI replacement, making them areas of focus for investment [5] Company Insights - Li Auto (LI US/2015 HK) reported a slight increase in gross margin to 17.8% for Q4 2025, exceeding expectations due to supplier rebates and strong performance from the i6 model [6] - The upcoming L9 model is critical for Li Auto's strategy, as its success may influence the positioning of future models like the L8 and L7 in a competitive SUV market [6] - Li Auto has revised its 2026 sales target down to approximately 490,000 units, reflecting challenges in inventory clearance and subsidy impacts, with expectations of a gross margin drop to around 5% in Q1 2025 [7][8]

Investment Rating - The report maintains a HOLD rating for Li Auto Inc. with a target price of US$18.00 for ADS and HK$70.00 for H-share, reflecting a slight upside potential of 1.0% for ADS and a minor downside of (0.2%) for H-share from current prices [3]. Core Insights - Li Auto is viewed as a strong company with potential for recovery due to its solid cash position, but the transition to an AI device company is expected to take time. The redesigned L9's outlook remains uncertain amid increased competition in the large SUV market [1][8]. - The company is projected to incur a net loss in the first half of FY26, and even with a successful launch of the L9, the valuation may still appear unattractive based on FY26 earnings estimates [1][8]. Financial Summary - Revenue projections show a significant increase from RMB 123.9 billion in FY23 to RMB 144.5 billion in FY24, followed by a decline to RMB 112.3 billion in FY25, before recovering to RMB 130.7 billion in FY26 and RMB 153.8 billion in FY27 [2][12]. - Gross margin is expected to decrease from 22.2% in FY23 to 20.5% in FY24, further declining to 18.7% in FY25, before slightly recovering to 17.6% in FY26 and 18.2% in FY27 [2][12]. - The net profit is forecasted to drop significantly from RMB 11.7 billion in FY23 to RMB 8.0 billion in FY24, then to RMB 1.1 billion in FY25, before rebounding to RMB 3.4 billion in FY26 and RMB 7.7 billion in FY27 [2][12]. Earnings Performance - In 4Q25, Li Auto's revenue exceeded prior forecasts by approximately 1%, with a gross profit margin increase of 1.5 percentage points to 17.8% quarter-over-quarter, attributed to better-than-expected performance from the i6 model and year-end supplier rebates [8]. - The company achieved a net profit of RMB 7 million in 4Q25, indicating a slight recovery despite ongoing challenges [8]. Sales Volume and Market Outlook - The sales volume target for FY26 has been revised down from over 500,000 units to approximately 490,000 units, reflecting a 20% year-over-year increase. The management anticipates vehicle gross profit margin to be around 5% in 1Q26 due to inventory clearance and tax benefits [8]. - The redesigned L9 and new i9 models are considered critical for the company's performance in the competitive large SUV market in China, with expectations of average monthly sales of over 10,000 units for the L9 [8].

Investment Rating - The report assigns a "Buy" rating to multiple companies, indicating a potential upside in their stock prices over the next 12 months [5][13]. Core Insights - The report highlights a basket of 26 stocks with an average return of -3.0%, which underperformed the MSCI China Index by 0.8 percentage points [10]. - Among the 26 stocks, 11 outperformed the benchmark, suggesting selective opportunities within the basket [10]. Summary by Relevant Sections Company Ratings - Companies such as Geely Automobile, Luckin Coffee, and Tencent are rated "Buy" with target prices indicating significant upside potential ranging from 38% to 109% [5]. - Specific target prices include: - Geely Automobile: 18.00 HKD (current price: 8.61 HKD) [5] - Luckin Coffee: 129.83 HKD (current price: 67.95 HKD) [5] - Tencent: 760.00 HKD (current price: 551.00 HKD) [5] Market Performance - The average market capitalization of the highlighted companies ranges from 1.3 billion to 641.3 billion, with varying average daily trading volumes [5]. - The report notes that the price-to-earnings (P/E) ratios for FY24A and FY25E show a wide range, indicating differing growth expectations across sectors [5]. Analyst Coverage - The report includes insights from multiple analysts, indicating a collaborative approach to stock evaluation [5].

Inflation Trends - The U.S. CPI and core CPI year-on-year growth rates remain stable at 2.4%, the lowest in nearly two years[2] - March CPI is expected to rise significantly to 3.1% due to a projected 17% increase in gasoline prices, contributing approximately 0.5 percentage points to the CPI growth[6] - Core CPI year-on-year growth is at a near five-year low of 2.5%, with core services growth slowing to 2.9%[6] Economic Risks - Rising oil prices are a major variable for future inflation, with a 10% increase in crude oil prices estimated to raise inflation by 0.3-0.4 percentage points[6] - The market's expectation for interest rate cuts has decreased from 60 basis points to 29 basis points, with the first anticipated cut pushed from June to September[6] - The ongoing Middle East conflict may prolong inflationary pressures, increasing the risk of stagflation in the U.S.[6] Core Components - Rent inflation continues to slow, currently at 0.2% month-on-month, with an annualized growth rate of 2.5%, below the pre-pandemic average of 3.3%[6] - Core goods inflation has slightly rebounded, with furniture, clothing, and leisure goods showing increases of 0.2%, 1.3%, and 0.4% respectively[6] - Core services, excluding rent, have a month-on-month growth rate of 0.35%, still reflecting high wage growth trends[6]

Industry Insights - The global weight loss drug market is projected to reach approximately $130 billion by 2034, with a compound annual growth rate (CAGR) of 13%-15% from 2024 to 2034, driven by a low penetration rate of about 1% among the over 900 million obese individuals worldwide [2][5] - The clinical advantages of tirzepatide, a dual receptor agonist, have led to a significant market share, capturing 67% of new prescriptions and 63% of total prescriptions in the U.S. by October 2025 [2][5] - The expansion of insurance coverage and decreasing drug prices in the U.S. are expected to catalyze demand, with Medicare Part D now covering weight loss treatments for patients with comorbidities [5] Technological Advancements - The development of weight loss drugs is focusing on four key areas: long-acting formulations, oral administration, enhanced efficacy, and muscle preservation during weight loss [6] - Notable advancements include Pfizer's monthly GLP-1 and insulin formulations, and oral small molecule GLP-1 receptor agonists from companies like Eli Lilly and Mondelēz [6][7] Company Analysis - The report highlights the potential of Gako's JAB-23E73 (pan-KRAS) as a groundbreaking drug, showing promising early efficacy and safety compared to competitors [8][9] - JAB-23E73 has demonstrated a treatment-related adverse event rate of 11.9%, significantly lower than the 34% observed with RMC-6236, indicating a favorable safety profile [9] - Gako's financial position is robust, with a cash balance of 1.13 billion RMB and expected revenue from partnerships, positioning the company well for future growth [11]

Investment Rating - The report maintains a BUY rating on Jacobio with a target price (TP) of HK$10.34, indicating a potential upside of 45.8% from the current price of HK$7.09 [1][2]. Core Insights - Jacobio's JAB-23E73 (pan-KRAS) has shown a highly differentiated safety profile and promising early efficacy, positioning it as a potential first-in-class blockbuster drug with estimated global risk-adjusted peak sales reaching US$2.1 billion [1]. - The company is well-capitalized with a strong financial position, reporting a cash balance of RMB1.13 billion and only RMB95 million in debt as of the end of 2025 [6]. - Jacobio is actively pursuing multiple clinical development catalysts, including a Ph1b/III trial in combination with chemotherapy for 1L PDAC and plans for a pivotal trial in China for 2L PDAC [6]. Financial Summary - Revenue projections show significant growth, with estimates of RMB 782 million for FY26E, followed by RMB 502 million in FY27E and RMB 531 million in FY28E [2][11]. - The net profit is expected to turn positive in FY26E, with an estimated net profit of RMB 487.5 million, followed by RMB 163.6 million in FY27E and RMB 47.7 million in FY28E [2][11]. - R&D expenses are projected to decrease in the coming years, with estimates of RMB 200 million in FY26E, RMB 300 million in FY27E, and RMB 398 million in FY28E [2][11]. Market Performance - Jacobio's market capitalization is approximately HK$5.61 billion, with a 52-week high of HK$11.60 and a low of HK$2.60 [3]. - The stock has shown a 1-month absolute performance of 13.6% and a relative performance of 19.6% [5]. Clinical Development - JAB-23E73 is the first pan-KRAS small molecule drug candidate to enter Ph1 study and release clinical data, demonstrating a significantly better safety profile compared to competitors [6]. - The ongoing Ph1 trial in the US and discussions with AstraZeneca for broader global development plans highlight the company's strategic partnerships and growth potential [6].

Macro Commentary - China's exports showed significant growth of 21.8% in the first two months of 2026, driven by a later Chinese New Year, low base effects, and an upturn in the global semiconductor industry [2] - Exports to the US saw a notable reduction in decline for the first time since Q2 2025, while imports rebounded significantly due to increased demand for AI-related materials [2] - The forecast for China's export growth is expected to slow slightly from 5.2% in 2025 to 4% in 2026, while imports are projected to recover from -0.5% to 2% [2] Market Performance - The Hang Seng Index closed at 25,960, up 2.17% for the day and 1.29% year-to-date [2] - The Shenzhen Component Index rose by 1.84% year-to-date, reflecting a strong performance in the Chinese stock market [2] - The US markets showed mixed results, with the S&P 500 and Dow Jones experiencing slight declines of 0.21% and 0.07% respectively [2] Company Commentary: NIO - NIO reported a 76% year-on-year revenue increase in Q4 2025, reaching 34.7 billion yuan, with a gross margin improvement of 3.6 percentage points to 17.5% [5] - The company achieved a non-GAAP operating profit of 1.25 billion yuan, exceeding previous forecasts, and recorded its first quarterly net profit of 122 million yuan [5] - Despite the positive results, NIO faces challenges in 2026 due to market competition, AI race, and fluctuations in component prices, leading to a slight reduction in sales forecasts [5][6] Profit Forecast and Valuation - Based on a sales assumption of 460,000 units for 2026, with five major models accounting for 60%, the forecasted gross margin is expected to rise to 16.3%, with net losses narrowing to 3.8 billion yuan [6] - NIO's brand value is recognized as a competitive advantage, but the costs associated with brand building may hinder overall profitability compared to peers [6] - The target price for NIO shares has been adjusted to $6 in the US and HK$47 in Hong Kong, based on a price-to-sales ratio of 0.8x for FY26E [6]